NIH Blueprint for Neuroscience Research Grand Challenge Developing Novel Drugs for Disorders of the Nervous System (U01) | Apply Online

Opportunity Summary:

The NIH Blueprint for Neuroscience Research Grand Challenge: Developing Novel Drugs for Disorders of the Nervous System (U01) is a cooperative agreement opportunity designed to help academic and other research teams move promising small-molecule neurotherapeutic leads closer to the clinic by plugging them into a "virtual pharma" drug development network. The central idea is to pair investigators who already have (1) a compelling disease-relevant assay or model and (2) a small-molecule starting compound (often described as a molecular probe or early lead) with a coordinated set of professional drug development capabilities that most NIH-funded labs cannot easily access on their own. This program is specifically aimed at projects where the biology looks promising but the compound is not yet at the stage where it is appropriate for clinical testing.

A key feature of this program is the combined support structure: awardees receive both direct grant funding to do assay-based biology work in their own laboratories and, separately, no-cost access to contracted drug development services arranged through the NIH. The funded portion supports activities like in vitro and/or in vivo screening of compound analogs in the applicant's disease assays and models, enabling the lab to generate the biological efficacy and mechanistic data needed to guide progression. In parallel, the program provides access to industry-style development work including medicinal chemistry optimization (to improve potency, selectivity, and drug-like properties), IND-directed pharmacology and toxicology (the kinds of studies needed to support an Investigational New Drug application), and even Phase I clinical testing for the most successful candidates. In other words, the program is meant to take a strong starting point and provide a structured path through key translational milestones that often stall purely academic efforts.

The opportunity is run under the NIH Research Project Cooperative Agreement (U01), which signals an active partnership between NIH and the awardees rather than a hands-off grant. Funded investigators are expected to be collaborative participants and active partners in shaping the development plan. They work alongside an NIH-appointed advisory panel made up of drug development experts, with the goal of designing and executing a realistic development strategy rather than just generating academic proof-of-concept data. This cooperative structure is intended to increase the odds that projects follow a credible path toward human testing, with decisions guided by translational "go/no-go" criteria typical of professional drug development.

In scope, the program is broad across disorders of the nervous system and is tied to the NIH Blueprint for Neuroscience, which spans 16 participating NIH Institutes and Centers. The announcement explicitly includes neurological, psychiatric, and developmental disorders, dementias associated with aging, disorders and diseases of the eye or ear, and substance use disorders including drug and alcohol dependence and addiction. That breadth is important because the program is not limited to one disease area; it is meant to advance novel targets and therapeutic concepts across the neuroscience landscape, as long as the proposal includes a promising small-molecule lead and a credible assay/model strategy relevant to a nervous system or psychiatric condition.

The NIH also sets clear program-level ambitions and expected throughput. Over a two-year period, the initiative anticipates initiating development on up to 20 new small-molecule compounds, with an expectation that around four compounds could reach Phase I clinical trials within the program. The longer-term goals are both practical and strategic: produce at least one novel and effective drug for a nervous system disorder that is currently poorly treated, and stimulate industry interest in new disease targets by demonstrating early-stage translational success. Put plainly, NIH is trying to de-risk innovative neuroscience targets and show enough momentum that private-sector partners may be willing to carry candidates further.

From a funding standpoint, the participating NIH Institutes and Centers planned to commit up to $1.75 million in FY2011 to support up to 10 awards in the first year, contingent on available funds and the quality of the application pool. Individual funded projects were anticipated to budget direct costs up to $125,000 per year for the in vitro and/or in vivo bioactivity screening performed in the investigator's lab, while the larger, high-cost development services (medicinal chemistry, IND-enabling studies, and Phase I testing) are provided separately at no cost to the awardee through NIH-managed contracts. This structure is meant to stretch limited grant dollars while still giving projects access to expensive, specialized development work.

The program also emphasizes intellectual property and commercialization considerations in a way that is meant to be attractive to academic inventors and small companies. The announcement indicates the program is structured so that investigators can maintain control of the intellectual property generated using their assays and starting compounds and can pursue commercialization of compounds developed within the program. That matters because translational drug development often depends on a clear IP pathway and the ability to form partnerships or spin out a venture if the science advances successfully.

Eligibility is wide and includes many organization types that commonly participate in NIH funding: public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), small businesses, and for-profit organizations. The eligibility language also explicitly includes several categories of institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, and even non-U.S. (foreign) entities, indicating an intent to cast a broad net for strong science and promising starting compounds wherever they are found.

Administrative details from the announcement include the Funding Opportunity Number RFA-NS-11-002, with the opportunity posted May 5, 2010, an original and current closing date of August 10, 2010, and an archive date of September 10, 2010. The sponsoring agency is the National Institutes of Health. The opportunity is categorized as a discretionary cooperative agreement, and it is associated with multiple CFDA program areas reflecting the cross-institute Blueprint structure, spanning neuroscience, mental health, aging, vision, deafness and communication disorders, addiction, alcohol, child health and development, and related biomedical research programs.

Taken together, this FOA is best understood as a translational "bridge" for neuroscience drug discovery: it is aimed at teams that already have a credible biological rationale, a useful disease assay or model, and an early small-molecule lead, and who need professional-grade development support to optimize the chemistry, generate IND-enabling data, and potentially reach first-in-human testing. The program is designed to combine academic innovation with a coordinated development infrastructure, while keeping investigators closely involved in strategic decisions and preserving a path to commercialization if a candidate succeeds.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Environment Health Income Security and Social Services

Next opportunity: Tribal Tobacco Control Programs to Reduce Commercial Tobacco Use Among American Indians and Alaska Natives

Previous opportunity: FY10 Region 04 Wetland Program Development Grants

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA NS 11 002

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA NS 11 002) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA NS 11 002", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.